3Ambrose PG, Rieherson MA. Stanton MD. et al. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia. Infections Disease in Clinical Practice.1999,8(5) :215.
4Klein NC, Gumha BA, Third-generation cephalosporins. Medical Clinics of North America, 1995,79 : 705.
5Brown R, Once daily ceftriaxone in the treatment of lower respiratory tract infections. Chemotherapy, 1991,37 : 11.
二级参考文献8
1[1]Knaus WA, Draper EA, Wagner DP, et al. APACHE Ⅱ: a severity of disease classification system. Crit Care Med, 1985, 13:818
2[2]Segreti J, Levin S. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin. Am J Med, 1996, 100(Suppl 6A):45
3[3]Leophonte P, Bertrand A, Nouvet G, et al. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicro Chemother, 1993, 31(Suppl B):165
4[4]Ambrose PG, Richerson MA, Stanton M, et al. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia. Infectious Disease in Clinical Practice, 1999, 8(5):245
5[5]Paladino JA. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis. Pharmaco Economics, 1994, 5(6):505
6[3]Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. London: Oxford University Press, 1996:26
7[5]Spilker B. Quality of life and pharmacoeconomics in clinical trails. Second edition. Philadephia: Lippincott-Raven Publish ers, 1996:253
